Wednesday, 18 November 2026NewsWorldBusinessTech
Latest

Researchers Develop Genetic Test Predicting Glaucoma Risk Decades Early

A new genetic screening test can predict the risk of developing glaucoma up to 25 years before clinical symptoms appear, according to research published in Ophthalmology in November 2026.

The study, led by researchers at Flinders University and QIMR Berghofer, utilizes polygenic risk scoring (PRS) to identify individuals susceptible to the disease and those likely to experience severe progression.

Glaucoma is the leading cause of irreversible blindness globally, but it often remains asymptomatic until permanent optic nerve damage has occurred. This genetic approach aims to provide a window for intervention before vision loss becomes permanent.

Genetic risk identifies high-risk individuals

The research found that genetic data can differentiate risk levels within populations. In individuals of European ancestry, those in the highest 10 percent of genetic risk were ten times more likely to develop glaucoma compared to the baseline population average, Scientific Frontline reported.

Professor Stuart MacGregor, head of QIMR Berghofer’s Statistical Genetics Laboratory, said the findings advance the field.

Genetic risk score forecasts glaucoma severity decades out
Photo: Ophthalmologytimes

“To our knowledge, this is the strongest genetic risk prediction reported for any common complex disease,” MacGregor said.

The predictive capability extends to the timing of the disease. The study indicated that individuals in the highest-risk group developed glaucoma up to 25 years earlier than those in the lowest-risk group.

A cohort study conducted by Tusa et al. utilized FinnGen Data Freeze 12, a resource that combines Finnish national health registries with germline genetic data for 402,739 individuals. Within this group, 21,609 people who received a glaucoma diagnosis after age 40 comprised the analytic cohort. The researchers evaluated lifetime glaucoma risk by age 85 and examined 20-year cumulative incidences of laser therapy, incisional surgery, and the escalation of medication to lower intraocular pressure.

New Genetic Test Could Detect Glaucoma Risk Before Sight Is Lost — 10 News

The PRS evaluated in this research incorporates more than 1 million genetic variants; the authors said that PRSs using larger numbers of variants generally showed better performance.

Predicting surgical necessity and costs

Beyond initial diagnosis, the polygenic risk score helps forecast the clinical trajectory of the disease.

The PRS also predicted incident and prevalent glaucoma surgery, treatment escalation in early disease, and open-angle glaucoma (OAG) risk among first-degree relatives.

Glaucoma-related health care costs were 1.6-fold greater in the highest PRS decile, with a median of €2,960, compared to a median of €1,849 in the lowest decile.

Risk Group Comparison Highest PRS Decile Lowest PRS Decile
Median healthcare costs €2,960 €1,849
Surgery requirement by age 80 Nearly 25 percent 0 percent

SightScore complements traditional clinical assessments

The technology is being developed to complement, rather than replace, traditional clinical assessments. Seonix Bio, a company founded in 2019, has developed the SightScore test, which uses a saliva sample to identify these genetic markers. SightScore’s PRS was evaluated across independent cohorts representing major ancestry groups using genome-wide association study data from more than 6 million individuals. The test was evaluated in Australian and U.S. cohorts, Healio reported.

“SightScore addresses the unmet need for early and accurate glaucoma risk assessment by using a polygenic risk score to identify individuals at high genetic risk before significant vision loss occurs,” Nick Haan, CEO of Seonix Bio, told Healio.

The clinical goal is to use genetic data to supplement standard assessments, which can assist in guiding personalized monitoring protocols and targeted screening. Identifying individuals with substantially elevated lifetime risk may help concentrate follow-up and screening resources.

Glaucoma care has traditionally relied on clinical measurements that may not fully capture a patient’s inherited risk or predict future disease course. Nick Haan

This research shows the potential of genetic information to add a meaningful dimension to risk assessment, not only helping identify who may develop glaucoma, but also providing insight into who may be more likely to progress and require surgery. Haan added

While the research shows promise, researchers note limitations regarding ancestry. The Tusa et al. cohort was comprised exclusively of Finnish (European) individuals, and the authors caution that findings may not generalize to other populations.

This is because polygenic risk scores typically exhibit reduced predictive accuracy in populations that differ from the training samples. Current performance is strongest in populations of European ancestry, and additional work is required to improve the equity of performance across diverse ancestries.

Research support has also been provided by the BrightFocus Foundation, the Ophthalmic Research Institute of Australia, and various grant numbers including 1107098, 1116360, 1116495, 1023911, and 1150144.

Individuals seeking to understand their personal risk for glaucoma should consult with a qualified medical professional or ophthalmologist.